Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity (unaudited) - USD ($) $ in Thousands |
Total |
Common Stock |
Additional Paid-In Capital |
Accumulated Other Comprehensive Income |
Accumulated Deficit |
Series A Convertible Preferred Stock |
Beginning balance (in shares) at Dec. 31, 2022 |
|
|
|
|
|
|
27,125,000
|
Beginning balance at Dec. 31, 2022 |
|
|
|
|
|
|
$ 27,125
|
Ending balance at Mar. 31, 2023 |
|
|
|
|
|
|
$ 27,125
|
Ending balance (in shares) at Mar. 31, 2023 |
|
|
|
|
|
|
27,125,000
|
Beginning balance (in shares) at Dec. 31, 2022 |
[1] |
|
867,499
|
|
|
|
|
Beginning balance at Dec. 31, 2022 |
|
$ (19,732)
|
$ 0
|
$ 195
|
$ 0
|
$ (19,927)
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
Stock-based compensation expense |
|
393
|
|
393
|
|
|
|
Net loss |
|
(7,502)
|
|
|
|
(7,502)
|
|
Ending balance at Mar. 31, 2023 |
|
(26,841)
|
$ 0
|
588
|
0
|
(27,429)
|
|
Ending balance (in shares) at Mar. 31, 2023 |
[1] |
|
867,499
|
|
|
|
|
Beginning balance (in shares) at Dec. 31, 2022 |
|
|
|
|
|
|
27,125,000
|
Beginning balance at Dec. 31, 2022 |
|
|
|
|
|
|
$ 27,125
|
Ending balance at Sep. 30, 2023 |
|
|
|
|
|
|
$ 127,772
|
Ending balance (in shares) at Sep. 30, 2023 |
|
|
|
|
|
|
128,148,529
|
Beginning balance (in shares) at Dec. 31, 2022 |
[1] |
|
867,499
|
|
|
|
|
Beginning balance at Dec. 31, 2022 |
|
$ (19,732)
|
$ 0
|
195
|
0
|
(19,927)
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
Issuance of common stock from exercise of stock options, including early exercises (in shares) |
|
1,800,000
|
|
|
|
|
|
Unrealized gain on investments |
|
$ 0
|
|
|
|
|
|
Net loss |
|
(29,222)
|
|
|
|
|
|
Ending balance at Sep. 30, 2023 |
|
(47,407)
|
$ 0
|
1,742
|
0
|
(49,149)
|
|
Ending balance (in shares) at Sep. 30, 2023 |
|
|
1,562,641
|
|
|
|
|
Beginning balance (in shares) at Mar. 31, 2023 |
|
|
|
|
|
|
27,125,000
|
Beginning balance at Mar. 31, 2023 |
|
|
|
|
|
|
$ 27,125
|
Increase (Decrease) in Temporary Equity [Roll Forward] |
|
|
|
|
|
|
|
Issuance of Series A convertible preferred units, net of issuance costs (in shares) |
|
|
|
|
|
|
92,200,000
|
Issuance of Series A convertible preferred stock, net of issuance costs |
|
|
|
|
|
|
$ 91,823
|
Issuance of Series A convertible preferred stock pursuant to anti-dilution provision of license agreement with Pfizer Inc. (in shares) |
|
|
|
|
|
|
8,823,529
|
Issuance of Series A convertible preferred stock pursuant to anti-dilution provision of the Pfizer License Agreement |
|
|
|
|
|
|
$ 8,824
|
Ending balance at Jun. 30, 2023 |
|
|
|
|
|
|
$ 127,772
|
Ending balance (in shares) at Jun. 30, 2023 |
|
|
|
|
|
|
128,148,529
|
Beginning balance (in shares) at Mar. 31, 2023 |
[1] |
|
867,499
|
|
|
|
|
Beginning balance at Mar. 31, 2023 |
|
(26,841)
|
$ 0
|
588
|
0
|
(27,429)
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
Stock-based compensation expense |
|
416
|
|
416
|
|
|
|
Issuance of common stock from exercise of stock options, including early exercises (in shares) |
[1] |
|
695,142
|
|
|
|
|
Issuance of common stock from exercise of stock options, including early exercises |
|
7
|
|
7
|
|
|
|
Vesting of early exercised stock options |
|
18
|
|
18
|
|
|
|
Net loss |
|
(16,129)
|
|
|
|
(16,129)
|
|
Ending balance at Jun. 30, 2023 |
|
(42,529)
|
$ 0
|
1,029
|
0
|
(43,558)
|
|
Ending balance (in shares) at Jun. 30, 2023 |
[1] |
|
1,562,641
|
|
|
|
|
Ending balance at Sep. 30, 2023 |
|
|
|
|
|
|
$ 127,772
|
Ending balance (in shares) at Sep. 30, 2023 |
|
|
|
|
|
|
128,148,529
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
Stock-based compensation expense |
|
$ 706
|
|
706
|
|
|
|
Issuance of common stock from exercise of stock options, including early exercises (in shares) |
|
0
|
|
|
|
|
|
Vesting of early exercised stock options |
|
$ 7
|
|
7
|
|
|
|
Unrealized gain on investments |
|
0
|
|
|
|
|
|
Net loss |
|
(5,591)
|
|
|
|
(5,591)
|
|
Ending balance at Sep. 30, 2023 |
|
$ (47,407)
|
$ 0
|
1,742
|
0
|
(49,149)
|
|
Ending balance (in shares) at Sep. 30, 2023 |
|
|
1,562,641
|
|
|
|
|
Beginning balance (in shares) at Dec. 31, 2023 |
|
|
|
|
|
|
0
|
Beginning balance at Dec. 31, 2023 |
|
|
|
|
|
|
$ 0
|
Ending balance at Mar. 31, 2024 |
|
|
|
|
|
|
$ 0
|
Ending balance (in shares) at Mar. 31, 2024 |
|
|
|
|
|
|
0
|
Beginning balance (in shares) at Dec. 31, 2023 |
|
20,337,571
|
20,337,571
|
|
|
|
|
Beginning balance at Dec. 31, 2023 |
|
$ 205,042
|
$ 2
|
267,024
|
67
|
(62,051)
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
Issuance of common stock from public offering, net of issuance costs (in shares) |
|
|
5,307,691
|
|
|
|
|
Issuance of common stock from public offering, net of issuance costs |
|
161,353
|
$ 1
|
161,352
|
|
|
|
Stock-based compensation expense |
|
1,388
|
|
1,388
|
|
|
|
Vesting of early exercised stock options |
|
7
|
|
7
|
|
|
|
Issuance of common stock upon vesting of restricted stock units (in shares) |
|
|
1,247
|
|
|
|
|
Unrealized gain on investments |
|
(320)
|
|
|
(320)
|
|
|
Net loss |
|
(13,311)
|
|
|
|
(13,311)
|
|
Ending balance at Mar. 31, 2024 |
|
$ 354,159
|
$ 3
|
429,771
|
(253)
|
(75,362)
|
|
Ending balance (in shares) at Mar. 31, 2024 |
|
|
25,646,509
|
|
|
|
|
Beginning balance (in shares) at Dec. 31, 2023 |
|
|
|
|
|
|
0
|
Beginning balance at Dec. 31, 2023 |
|
|
|
|
|
|
$ 0
|
Ending balance at Sep. 30, 2024 |
|
|
|
|
|
|
$ 0
|
Ending balance (in shares) at Sep. 30, 2024 |
|
|
|
|
|
|
0
|
Beginning balance (in shares) at Dec. 31, 2023 |
|
20,337,571
|
20,337,571
|
|
|
|
|
Beginning balance at Dec. 31, 2023 |
|
$ 205,042
|
$ 2
|
267,024
|
67
|
(62,051)
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
Issuance of common stock from exercise of stock options, including early exercises (in shares) |
|
0
|
|
|
|
|
|
Unrealized gain on investments |
|
$ 754
|
|
|
|
|
|
Net loss |
|
(50,975)
|
|
|
|
|
|
Ending balance at Sep. 30, 2024 |
|
$ 321,068
|
$ 3
|
433,270
|
821
|
(113,026)
|
|
Ending balance (in shares) at Sep. 30, 2024 |
|
25,642,610
|
25,642,610
|
|
|
|
|
Beginning balance (in shares) at Mar. 31, 2024 |
|
|
|
|
|
|
0
|
Beginning balance at Mar. 31, 2024 |
|
|
|
|
|
|
$ 0
|
Ending balance at Jun. 30, 2024 |
|
|
|
|
|
|
$ 0
|
Ending balance (in shares) at Jun. 30, 2024 |
|
|
|
|
|
|
0
|
Beginning balance (in shares) at Mar. 31, 2024 |
|
|
25,646,509
|
|
|
|
|
Beginning balance at Mar. 31, 2024 |
|
$ 354,159
|
$ 3
|
429,771
|
(253)
|
(75,362)
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
Stock-based compensation expense |
|
1,789
|
|
1,789
|
|
|
|
Vesting of early exercised stock options |
|
20
|
|
20
|
|
|
|
Issuance of common stock upon vesting of restricted stock units (in shares) |
|
|
1,246
|
|
|
|
|
Unrealized gain on investments |
|
(199)
|
|
|
(199)
|
|
|
Net loss |
|
(17,487)
|
|
|
|
(17,487)
|
|
Ending balance at Jun. 30, 2024 |
|
338,282
|
$ 3
|
431,580
|
(452)
|
(92,849)
|
|
Ending balance (in shares) at Jun. 30, 2024 |
|
|
25,647,755
|
|
|
|
|
Ending balance at Sep. 30, 2024 |
|
|
|
|
|
|
$ 0
|
Ending balance (in shares) at Sep. 30, 2024 |
|
|
|
|
|
|
0
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
Stock-based compensation expense |
|
$ 1,681
|
|
1,681
|
|
|
|
Issuance of common stock from exercise of stock options, including early exercises (in shares) |
|
0
|
|
|
|
|
|
Vesting of early exercised stock options |
|
$ 9
|
|
9
|
|
|
|
Repurchase of common stock (in shares) |
|
|
(6,392)
|
|
|
|
|
Issuance of common stock upon vesting of restricted stock units (in shares) |
|
|
1,247
|
|
|
|
|
Unrealized gain on investments |
|
1,273
|
|
|
1,273
|
|
|
Net loss |
|
(20,177)
|
|
|
|
(20,177)
|
|
Ending balance at Sep. 30, 2024 |
|
$ 321,068
|
$ 3
|
$ 433,270
|
$ 821
|
$ (113,026)
|
|
Ending balance (in shares) at Sep. 30, 2024 |
|
25,642,610
|
25,642,610
|
|
|
|
|
|
|